An emergency authorisation for Bimectin broadens the cattle-sector response to New World screwworm.

The U.S. Food and Drug Administration has added a generic cattle treatment to the emergency response against (NWS) infestations (myiasis), a development that could widen producers access to preventive options where the parasite presents a material risk. The decision is commercially important because it addresses a livestock threat through a product route that is not limited to a single manufacturer.

On 27 August, FDA issued an Emergency Use Authorization for Bimectin, an ivermectin injection, for prevention of New World screwworm infestations in cattle. The authorisation covers administration within 24 hours of birth, at castration or when a wound appears. FDA specified that Bimectin is not authorised for use in lactating dairy cows or calves intended for veal processing.

FDA described the action as its 14th emergency use authorisation against New World screwworm and said the aim was to expand generic drug options. In a production setting, that distinction matters. Disease events create costs through animal losses, treatment, labour, movement restrictions and disrupted marketing. More than one authorised product pathway can improve procurement flexibility, although availability, veterinary protocols and label conditions still determine whether the option can be used on a particular operation.

The details of the authorisation also underline why broad headlines need careful reading. The product is authorised for prevention in cattle at defined moments of heightened wound-related exposure; it is not a blanket instruction for every class of cattle. The exclusions for lactating dairy cows and veal-bound calves are operational constraints that dairy and integrated systems will need to accommodate in their own disease-control plans.

This is an emergency-use measure, not a replacement for surveillance, biosecurity or veterinary oversight. Its value lies in adding a practical tool to a wider response. For suppliers, producers and veterinarians, the next commercial question is how quickly authorised options can be integrated into consistent protocols without compromising residue, animal-welfare or market-access requirements.

For further info: U.S. Food and Drug Administration